Clinical applications of the Model for End-Stage Liver Disease (MELD) in hepatic medicine
Tsang Lau, Jawad AhmadDivision of Liver Diseases, Mount Sinai School of Medicine, New York, USAAbstract: The Model for End-Stage Liver Disease (MELD) score incorporates serum bilirubin, creatinine, and the international normalized ratio (INR) into a formula that provides a continuous variable that i...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2013-02-01
|
Series: | Hepatic Medicine : Evidence and Research |
Online Access: | http://www.dovepress.com/clinical-applications-of-the-model-for-end-stage-liver-disease-meld-in-a12174 |
id |
doaj-c415818656d44382b482834626c1adba |
---|---|
record_format |
Article |
spelling |
doaj-c415818656d44382b482834626c1adba2020-11-24T22:04:05ZengDove Medical PressHepatic Medicine : Evidence and Research1179-15352013-02-012013default110Clinical applications of the Model for End-Stage Liver Disease (MELD) in hepatic medicineLau TAhmad JTsang Lau, Jawad AhmadDivision of Liver Diseases, Mount Sinai School of Medicine, New York, USAAbstract: The Model for End-Stage Liver Disease (MELD) score incorporates serum bilirubin, creatinine, and the international normalized ratio (INR) into a formula that provides a continuous variable that is a very accurate predictor of 90-day mortality in patients with cirrhosis. It is currently utilized in the United States to prioritize deceased donor organ allocation for patients listed for liver transplantation. The MELD score is superior to other prognostic models in patients with end-stage liver disease, such as the Child–Turcotte–Pugh score, since it uses only objective criteria, and its implementation in 2002 led to a sharp reduction in the number of people waiting for liver transplant and reduced mortality on the waiting list without affecting posttransplant survival. Although mainly adopted for use in patients waiting for liver transplant, the MELD score has also proved to be an effective predictor of outcome in other situations, such as patients with cirrhosis going for surgery and patients with fulminant hepatic failure or alcoholic hepatitis. Several variations of the original MELD score, involving the addition of serum sodium or looking at the change in MELD over time, have been examined, and these may slightly improve its accuracy. The MELD score does have limitations in situations where the INR or creatinine may be elevated due to reasons other than liver disease, and its implementation for organ allocation purposes does not take into consideration several conditions that benefit from liver transplantation. The application of the MELD score in prioritizing patients for liver transplantation has been successful, but further studies and legislation are required to ensure a fair and equitable system.Keywords: MELD score, liver transplantationhttp://www.dovepress.com/clinical-applications-of-the-model-for-end-stage-liver-disease-meld-in-a12174 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Lau T Ahmad J |
spellingShingle |
Lau T Ahmad J Clinical applications of the Model for End-Stage Liver Disease (MELD) in hepatic medicine Hepatic Medicine : Evidence and Research |
author_facet |
Lau T Ahmad J |
author_sort |
Lau T |
title |
Clinical applications of the Model for End-Stage Liver Disease (MELD) in hepatic medicine |
title_short |
Clinical applications of the Model for End-Stage Liver Disease (MELD) in hepatic medicine |
title_full |
Clinical applications of the Model for End-Stage Liver Disease (MELD) in hepatic medicine |
title_fullStr |
Clinical applications of the Model for End-Stage Liver Disease (MELD) in hepatic medicine |
title_full_unstemmed |
Clinical applications of the Model for End-Stage Liver Disease (MELD) in hepatic medicine |
title_sort |
clinical applications of the model for end-stage liver disease (meld) in hepatic medicine |
publisher |
Dove Medical Press |
series |
Hepatic Medicine : Evidence and Research |
issn |
1179-1535 |
publishDate |
2013-02-01 |
description |
Tsang Lau, Jawad AhmadDivision of Liver Diseases, Mount Sinai School of Medicine, New York, USAAbstract: The Model for End-Stage Liver Disease (MELD) score incorporates serum bilirubin, creatinine, and the international normalized ratio (INR) into a formula that provides a continuous variable that is a very accurate predictor of 90-day mortality in patients with cirrhosis. It is currently utilized in the United States to prioritize deceased donor organ allocation for patients listed for liver transplantation. The MELD score is superior to other prognostic models in patients with end-stage liver disease, such as the Child–Turcotte–Pugh score, since it uses only objective criteria, and its implementation in 2002 led to a sharp reduction in the number of people waiting for liver transplant and reduced mortality on the waiting list without affecting posttransplant survival. Although mainly adopted for use in patients waiting for liver transplant, the MELD score has also proved to be an effective predictor of outcome in other situations, such as patients with cirrhosis going for surgery and patients with fulminant hepatic failure or alcoholic hepatitis. Several variations of the original MELD score, involving the addition of serum sodium or looking at the change in MELD over time, have been examined, and these may slightly improve its accuracy. The MELD score does have limitations in situations where the INR or creatinine may be elevated due to reasons other than liver disease, and its implementation for organ allocation purposes does not take into consideration several conditions that benefit from liver transplantation. The application of the MELD score in prioritizing patients for liver transplantation has been successful, but further studies and legislation are required to ensure a fair and equitable system.Keywords: MELD score, liver transplantation |
url |
http://www.dovepress.com/clinical-applications-of-the-model-for-end-stage-liver-disease-meld-in-a12174 |
work_keys_str_mv |
AT laut clinicalapplicationsofthemodelforendstageliverdiseasemeldinhepaticmedicine AT ahmadj clinicalapplicationsofthemodelforendstageliverdiseasemeldinhepaticmedicine |
_version_ |
1725830549805727744 |